Miracle cures are few and far between. The best one can hope for is partial relief. So it is with Sanofi’s consumer health split. The French pharma group’s sale of a majority 50 per cent stake in its Opella unit to Clayton Dubilier & Rice leaves all participants with some ills to address.
奇跡般的治療方法少之又少。人們所能期待的最好結(jié)果也只是部分緩解。賽諾菲的消費(fèi)者健康業(yè)務(wù)分拆也是如此。這家法國制藥集團(tuán)將其Opella部門50%的多數(shù)股權(quán)出售給Clayton Dubilier & Rice公司后，所有參與者都面臨著一些亟待解決的問題。
您已閱讀12%（415字），剩余88%（3051字）包含更多重要信息，訂閱以繼續(xù)探索完整內(nèi)容，并享受更多專屬服務(wù)。